Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Vanda Pharmaceuticals stock

VNDA
US9216591084
A0JJT3

Price

0
Today +/-
-0
Today %
-0 %

Vanda Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Vanda Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Vanda Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Vanda Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Vanda Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Vanda Pharmaceuticals Stock Price History

DateVanda Pharmaceuticals Price
2/10/20250 undefined
2/6/20254.80 undefined
2/5/20254.69 undefined
2/4/20254.53 undefined
2/3/20254.48 undefined
2/2/20254.31 undefined
1/30/20254.41 undefined
1/29/20254.58 undefined
1/28/20254.53 undefined
1/27/20254.44 undefined
1/26/20254.45 undefined
1/23/20254.40 undefined
1/22/20254.42 undefined
1/21/20254.35 undefined
1/20/20254.51 undefined
1/16/20254.36 undefined
1/15/20254.44 undefined
1/14/20254.45 undefined
1/13/20254.38 undefined
1/12/20254.53 undefined

Vanda Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Vanda Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Vanda Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Vanda Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Vanda Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Vanda Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Vanda Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Vanda Pharmaceuticals’s growth potential.

Vanda Pharmaceuticals Revenue, EBIT and net profit per share

DateVanda Pharmaceuticals RevenueVanda Pharmaceuticals EBITVanda Pharmaceuticals Net Income
2028e245.82 M undefined0 undefined0 undefined
2027e295.8 M undefined20.4 M undefined0 undefined
2026e336.3 M undefined46.35 M undefined60.07 M undefined
2025e290.6 M undefined-1.83 M undefined12.09 M undefined
2024e203.43 M undefined-41.15 M undefined-19.03 M undefined
2023192.64 M undefined-13.95 M undefined2.51 M undefined
2022254.4 M undefined6.3 M undefined6.3 M undefined
2021268.7 M undefined62 M undefined33.2 M undefined
2020248.2 M undefined34.1 M undefined23.3 M undefined
2019227.2 M undefined22.8 M undefined115.6 M undefined
2018193.1 M undefined21.7 M undefined25.2 M undefined
2017165.1 M undefined-16.9 M undefined-15.6 M undefined
2016146 M undefined-18.6 M undefined-18 M undefined
2015109.9 M undefined-40.2 M undefined-39.9 M undefined
201450.2 M undefined-57.5 M undefined20.2 M undefined
201333.9 M undefined-21.2 M undefined-21.1 M undefined
201232.7 M undefined-29.2 M undefined-28.6 M undefined
201131.3 M undefined-10.7 M undefined-9.8 M undefined
201035.7 M undefined8.8 M undefined7.2 M undefined
20094.5 M undefined-35.9 M undefined-35.9 M undefined
20080 undefined-52.8 M undefined-51.1 M undefined
20070 undefined-80 M undefined-74.1 M undefined
20060 undefined-52.1 M undefined-49.9 M undefined
20050 undefined-16.9 M undefined-50 M undefined
20040 undefined-7.4 M undefined-7.4 M undefined

Vanda Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
00000043531323350109146165193227248268254192203290336295245
-------775.00-11.433.233.1351.52118.0033.9413.0116.9717.629.258.06-5.22-24.415.7342.8615.86-12.20-16.95
------50.0091.43100.00100.00100.0096.0078.9082.8889.0989.1288.9990.3290.6790.5592.1987.1961.0352.6860.0072.24
000000232313233488612114717220222424323017700000
-1-7-50-49-74-51-357-9-28-2120-39-18-1525115233362-19126000
-600.00614.29-2.0051.02-31.08-31.37-120.00-228.57211.11-25.00-195.24-295.00-53.85-16.67-266.67360.00-80.0043.48-81.82-66.67-1,050.00-163.16400.00--
21.621.621.61626.426.72728.528.128.230.436.742.343.444.75354.855.256.95757.5600000
--------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Vanda Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Vanda Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                         
7.216.331.231.985.246.5205.3198148.9120.4130.4129.8143.2141.3143.4257.4312.1367.7432.8466.9388.26
0000003.20.51.61.223.716.320.317.628.826.43032.533.534.16
000000000000000000000
0000002.400005.21.30.80.811.11.311.21.36
0.10.22.21.91.81.32.1234.43.33.15.711.881214.510.11217.79.17
7.316.533.433.88747.8213200.5153.5126135.7141.8166.5174.2169.8299.2354.1409.1478.3519.3432.95
1.11.31.11.91.31.81.30.912.32.22.44.655.34.41514.612.4119.14
00.10.80.28.100019000000000000
000000000000000000000
000000119.586.5526.738.827.826.124.52321.620.118.6121.37
000000000000000000000
000.40.40.40.40.42.11.10.60.50.83.23.44.2491.588.28385.484.99
1.11.42.32.59.82.212.712.529.19.47.729.946.636.235.632.9129.5124.4115.5115215.49
8.417.935.736.396.850225.7213182.6135.4143.4171.7213.1210.4205.4332.1483.6533.5593.8634.3648.44
                                         
1028.361.80000000000000.10.10.10.10.10.06
00.324126.6257.6271283.8291.3296.9301352.2448.7460.8477.1492.8611.6631.3650.3669.2686.2700.27
-3-12.4-36.3-99.8-173.9-225-260.8-253.6-263.4-291.1-308.2-288-327.8-345.9-361.4-336.2-220.7-197.3-164.2-157.9-155.39
0-300-18,80000000000001000001000021
0000000000000000200200-200-1,200-51
715.930.726.883.7462337.733.59.944160.7133131.3131.4275.5410.9453.4504.9527.2544.91
0.50.72.32.830.52.40.610.30.71.45.34.64.45.25.95.85.952.41
0.40.72.56.39.82.92.31.33.45.25.26.34645.83947.653.659.868.586.585.29
000.100026.829.127.226.827000270.200.4000
000000000000000000000
200200100000000000000000000
1.11.659.112.83.431.53131.632.332.97.751.350.470.45359.56674.491.587.7
3002000000000000000000000
000000000000000000000
0000.40.40.5171.1144.3117.593.366.43.128.728.73.73.713.314.314.415.615.83
0.30.200.40.40.5171.1144.3117.593.366.43.128.728.73.73.713.314.314.415.615.83
1.41.859.513.23.9202.6175.3149.1125.699.310.88079.174.156.772.880.388.8107.1103.53
8.417.735.736.396.949.9225.6213182.6135.5143.3171.5213210.4205.5332.2483.7533.7593.7634.3648.44
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Vanda Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Vanda Pharmaceuticals's financial health and stability.

Assets

Vanda Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Vanda Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Vanda Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Vanda Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-3-9-23-63-74-51-357-9-28-2120-39-18-1525115233362
00000011221213113222223
0000000-110000000-87661-1
00053-8192-20-28-24-26-3330-110-734260
00553726227111011-65161721212528343223
000000000000000000000
000000000000000000003
-2-8-17-51-51-46169-10-28-44-39-8112-8-2304551643212
-100-100-1200-20-8-2-1-1-25-1-1000
-10-108-4843-4-1557345-34-12-26-10-10-109-68-41-7649-12
00-109-48447-1557447-34-3-24-8-8-84-67-39-7650-11
000000000000000000000
000000000000000000000
1018335311101000509047510765300
1018335311101300498947510765300
000000020000000000000
000000000000000000000
794911-2166-162450-24-3-10-10-627-1616-9820
-3.3-9-18-53-51.9-46.9157.3-10.9-28.7-46.9-39.8-90.49.9-9.5-3.74.644.95063.631.312.42
000000000000000000000

Vanda Pharmaceuticals stock margins

The Vanda Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vanda Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vanda Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Vanda Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Vanda Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Vanda Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Vanda Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Vanda Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Vanda Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Vanda Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Vanda Pharmaceuticals Margin History

Vanda Pharmaceuticals Gross marginVanda Pharmaceuticals Profit marginVanda Pharmaceuticals EBIT marginVanda Pharmaceuticals Profit margin
2028e92.32 %0 %0 %
2027e92.32 %6.9 %0 %
2026e92.32 %13.78 %17.86 %
2025e92.32 %-0.63 %4.16 %
2024e92.32 %-20.23 %-9.36 %
202392.32 %-7.24 %1.3 %
202290.45 %2.48 %2.48 %
202190.47 %23.07 %12.36 %
202090.57 %13.74 %9.39 %
201989.22 %10.04 %50.88 %
201889.38 %11.24 %13.05 %
201789.16 %-10.24 %-9.45 %
201683.08 %-12.74 %-12.33 %
201578.71 %-36.58 %-36.31 %
201496.81 %-114.54 %40.24 %
2013100 %-62.54 %-62.24 %
201299.69 %-89.3 %-87.46 %
2011100 %-34.19 %-31.31 %
201091.88 %24.65 %20.17 %
200957.78 %-797.78 %-797.78 %
200892.32 %0 %0 %
200792.32 %0 %0 %
200692.32 %0 %0 %
200592.32 %0 %0 %
200492.32 %0 %0 %

Vanda Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Vanda Pharmaceuticals earnings per share therefore indicates how much revenue Vanda Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vanda Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vanda Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vanda Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vanda Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vanda Pharmaceuticals Revenue, EBIT and net profit per share

DateVanda Pharmaceuticals Sales per ShareVanda Pharmaceuticals EBIT per shareVanda Pharmaceuticals Earnings per Share
2028e4.22 undefined0 undefined0 undefined
2027e5.07 undefined0 undefined0 undefined
2026e5.77 undefined0 undefined1.03 undefined
2025e4.98 undefined0 undefined0.21 undefined
2024e3.49 undefined0 undefined-0.33 undefined
20233.35 undefined-0.24 undefined0.04 undefined
20224.46 undefined0.11 undefined0.11 undefined
20214.72 undefined1.09 undefined0.58 undefined
20204.5 undefined0.62 undefined0.42 undefined
20194.15 undefined0.42 undefined2.11 undefined
20183.64 undefined0.41 undefined0.48 undefined
20173.69 undefined-0.38 undefined-0.35 undefined
20163.36 undefined-0.43 undefined-0.41 undefined
20152.6 undefined-0.95 undefined-0.94 undefined
20141.37 undefined-1.57 undefined0.55 undefined
20131.12 undefined-0.7 undefined-0.69 undefined
20121.16 undefined-1.04 undefined-1.01 undefined
20111.11 undefined-0.38 undefined-0.35 undefined
20101.25 undefined0.31 undefined0.25 undefined
20090.17 undefined-1.33 undefined-1.33 undefined
20080 undefined-1.98 undefined-1.91 undefined
20070 undefined-3.03 undefined-2.81 undefined
20060 undefined-3.26 undefined-3.12 undefined
20050 undefined-0.78 undefined-2.31 undefined
20040 undefined-0.34 undefined-0.34 undefined

Vanda Pharmaceuticals business model

Vanda Pharmaceuticals Inc is a US biotechnology company specializing in the development and marketing of innovative therapies for neurological, psychiatric, and cardiovascular diseases. It was founded in 2002 by Mihael H. Polymeropoulos, who previously worked as a senior researcher at the genetic research company Novartis. Vanda Pharmaceuticals is based in Washington D.C. The company's business model focuses on developing and bringing to market medicines for rare diseases. It collaborates closely with clinics and research institutes to tailor innovative therapies and medications to the specific needs of patients. Vanda Pharmaceuticals operates in various areas, including neurology, psychiatry, and cardiology. In neurology, the company focuses on researching and developing therapies for rare diseases such as isolated sleeplessness syndrome and delayed sleep phase syndrome. In psychiatry, Vanda Pharmaceuticals has brought several medications to market for the treatment of schizophrenia, bipolar disorder, and depression. The medication Fanapt, in particular, has become a successful schizophrenia medication and has already been approved by the US FDA. In cardiology, Vanda Pharmaceuticals is working on the development of medications for the treatment of cardiovascular diseases such as heart failure and high blood pressure. One of Vanda Pharmaceuticals' most innovative therapy forms is chronotherapy, which involves timing the intake of certain medications to the body's natural circadian rhythm. The goal of chronotherapy is to maximize treatment effectiveness while minimizing side effects. An example of Vanda Pharmaceuticals' successes is the aforementioned medication Fanapt, which was approved by the FDA in 2009 and is distributed worldwide. Clinical studies have shown that Fanapt is safe and effective in the treatment of schizophrenia. The high expectations for the medication have led to Vanda Pharmaceuticals' listing on the NASDAQ and the company having a market value of several hundred million dollars. In conclusion, Vanda Pharmaceuticals is an innovative biotechnology company specializing in the research and development of therapies for rare diseases. With the successful introduction of medications like Fanapt, the company has established itself as an important player in the American and international markets. Vanda Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Vanda Pharmaceuticals SWOT Analysis

Strengths

Vanda Pharmaceuticals Inc has a strong portfolio of innovative and patented drugs, offering a competitive advantage in the pharmaceutical industry. The company's research and development capabilities are robust, allowing it to continuously develop and bring new drugs to market. Vanda Pharmaceuticals also has a dedicated and skilled workforce, contributing to its overall strength.

  • Strong portfolio of patented drugs
  • Robust research and development capabilities
  • Dedicated and skilled workforce

Weaknesses

One of the weaknesses of Vanda Pharmaceuticals Inc is its dependence on limited drug offerings. The company's revenue streams heavily rely on a few key drugs, making it vulnerable to competition and potential market fluctuations. Another weakness is the high costs associated with drug development and regulatory processes.

  • Dependence on limited drug offerings
  • Vulnerability to competition and market fluctuations
  • High costs of drug development and regulatory processes

Opportunities

Vanda Pharmaceuticals Inc has several opportunities for growth and expansion. The increasing prevalence of certain medical conditions, for which the company offers effective drug treatments, presents a favorable market environment. Vanda Pharmaceuticals can also capitalize on strategic partnerships and collaborations to access new markets and enhance its product offerings.

  • Growing market demand for drugs targeting specific medical conditions
  • Potential for strategic partnerships and collaborations
  • Expansion into new markets

Threats

Vanda Pharmaceuticals Inc faces various threats that could impact its performance and market position. One significant threat is the potential loss of patents and exclusivity rights, which would expose the company's drugs to generic competition. Additionally, changes in government regulations and policies, as well as adverse events related to drug safety, pose threats to Vanda Pharmaceuticals' operations.

  • Potential loss of patents and exclusivity rights
  • Generic competition
  • Changes in government regulations and policies
  • Adverse events related to drug safety

Vanda Pharmaceuticals Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Vanda Pharmaceuticals Revenue by Segment

Segmente20222021202020192018
HETLIOZ®159.66 M USD173.54 M USD160.69 M USD--
Fanapt®94.73 M USD95.15 M USD87.48 M USD84.21 M USD77.28 M USD

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Vanda Pharmaceuticals Revenue by Segment

Segmente20222021202020192018
HETLIOZ®---142.98 M USD115.84 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Vanda Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Vanda Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Vanda Pharmaceuticals shares outstanding

The number of shares was Vanda Pharmaceuticals in 2024 — This indicates how many shares 57.558 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vanda Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vanda Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vanda Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vanda Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Vanda Pharmaceuticals.

Vanda Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.17 -0.09  (45.98 %)2024 Q3
6/30/2024-0.21 -0.08  (62.65 %)2024 Q2
3/31/20240.05 -0.07  (-237.25 %)2024 Q1
12/31/2023-0.09 -0.04  (56.43 %)2023 Q4
9/30/2023-0.04 0  (100 %)2023 Q3
6/30/2023-0.13 0.03  (122.62 %)2023 Q2
3/31/20230 0.06  (0 %)2023 Q1
12/31/20220.08 0.12  (47.06 %)2022 Q4
9/30/20220.09 0.06  (-34.64 %)2022 Q3
6/30/20220.14 0.05  (-64.99 %)2022 Q2
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Vanda Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

42/ 100

🌱 Environment

45

👫 Social

50

🏛️ Governance

32

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Vanda Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
9.48542 % BlackRock Institutional Trust Company, N.A.5,530,947136,8826/30/2024
7.05561 % Renaissance Technologies LLC4,114,125-161,5006/30/2024
5.86520 % The Vanguard Group, Inc.3,419,99736,0886/30/2024
3.69286 % Tang Capital Management, LLC2,153,307401,6536/30/2024
3.45362 % Dimensional Fund Advisors, L.P.2,013,807292,1726/30/2024
3.39912 % Acadian Asset Management LLC1,982,027-388,3086/30/2024
3.01371 % BlackRock Financial Management, Inc.1,757,294-159,0676/30/2024
2.73283 % Nantahala Capital Management, LLC1,593,516580,2656/30/2024
2.54890 % Jacobs Levy Equity Management, Inc.1,486,26266,7026/30/2024
2.28255 % Geode Capital Management, L.L.C.1,330,95785,5756/30/2024
1
2
3
4
5
...
10

Vanda Pharmaceuticals Executives and Management Board

Dr. Mihael Polymeropoulos

(63)
Vanda Pharmaceuticals Chairman of the Board, President, Chief Executive Officer (since 2003)
Compensation 4.27 M

Mr. Joakim Wijkstrom

(57)
Vanda Pharmaceuticals Senior Vice President, Chief Marketing Officer
Compensation 1.62 M

Mr. Timothy Williams

(47)
Vanda Pharmaceuticals Senior Vice President, General Counsel, Secretary
Compensation 1.5 M

Mr. Gunther Birznieks

(54)
Vanda Pharmaceuticals Senior Vice President - Business Development
Compensation 1.47 M

Mr. Kevin Moran

(39)
Vanda Pharmaceuticals Chief Financial Officer, Senior Vice President, Treasurer
Compensation 1.44 M
1
2

Vanda Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Omnicom Stock
Omnicom
SupplierCustomer0,710,490,67-0,44-0,440,51
Novartis Stock
Novartis
SupplierCustomer0,650,46-0,86-0,72-0,15-0,04
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer0,220,380,690,810,050,30
AmerisourceBergen Stock
AmerisourceBergen
SupplierCustomer0,20-0,160,04-0,87-0,91-0,02
Formosa Laboratories Stock
Formosa Laboratories
SupplierCustomer0,200,450,150,060,580,51
Cigna Stock
Cigna
SupplierCustomer0,05-0,45-0,54-0,77-0,610,36
McKesson Stock
McKesson
SupplierCustomer0,04-0,48-0,47-0,91-0,93-0,11
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer-0,07-0,22-0,47-0,90-0,69-0,19
UnitedHealth Group Stock
UnitedHealth Group
SupplierCustomer-0,120,430,48-0,42-0,770,15
Cardinal Health Stock
Cardinal Health
SupplierCustomer-0,270,440,08-0,74-0,370,13
1

Most common questions regarding Vanda Pharmaceuticals

What values and corporate philosophy does Vanda Pharmaceuticals represent?

Vanda Pharmaceuticals Inc is a leading biopharmaceutical company that specializes in the development and commercialization of innovative therapies. With a focus on addressing unmet medical needs, Vanda Pharmaceuticals is dedicated to providing effective treatment options for patients worldwide. The company prides itself on its commitment to scientific excellence, ethical practices, and patient-centric values. By leveraging its extensive expertise in neuroscience and clinical development, Vanda Pharmaceuticals aims to improve the lives of individuals suffering from central nervous system disorders. With its passion for innovation and dedication to improving patient outcomes, Vanda Pharmaceuticals Inc embodies a strong corporate philosophy centered on advancing healthcare solutions.

In which countries and regions is Vanda Pharmaceuticals primarily present?

Vanda Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Vanda Pharmaceuticals achieved?

Vanda Pharmaceuticals Inc has achieved several significant milestones. The company received FDA approval for Fanapt®, an antipsychotic medication, in 2009. In 2013, they gained FDA approval for Hetlioz®, a treatment for Non-24-Hour Sleep-Wake Disorder. Vanda Pharmaceuticals has also actively developed partnerships, such as their collaboration with Novartis to commercialize Fanapt® in the US. As a global biopharmaceutical company, Vanda Pharmaceuticals Inc continues to advance research and development for innovative therapies, aiming to improve patients' lives.

What is the history and background of the company Vanda Pharmaceuticals?

Vanda Pharmaceuticals Inc. is a renowned biopharmaceutical company with a rich history and impressive background. Founded in 2002 and headquartered in Washington, D.C., Vanda Pharmaceuticals Inc. focuses on the development and commercialization of innovative therapies to address critical medical needs. Leveraging their expertise in clinical development, the company has successfully brought several groundbreaking products to market, particularly in the fields of neurology and psychiatry. With a strong commitment to improving patient outcomes, Vanda Pharmaceuticals Inc. continues to invest in research and development to pioneer new treatment options and enhance the lives of individuals worldwide.

Who are the main competitors of Vanda Pharmaceuticals in the market?

The main competitors of Vanda Pharmaceuticals Inc in the market include companies like Novartis AG, Jazz Pharmaceuticals, and Supernus Pharmaceuticals.

In which industries is Vanda Pharmaceuticals primarily active?

Vanda Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Vanda Pharmaceuticals?

The business model of Vanda Pharmaceuticals Inc is focused on developing, commercializing, and marketing pharmaceutical products. As a biopharmaceutical company, Vanda Pharmaceuticals specializes in the discovery and development of innovative therapies to address unmet medical needs. With a strategic focus on central nervous system disorders, Vanda Pharmaceuticals aims to deliver effective treatments that improve the lives of patients. Through research, clinical trials, and product commercialization, Vanda Pharmaceuticals strives to bring novel and differentiated therapeutic options to the market.

What is the P/E ratio of Vanda Pharmaceuticals 2025?

The P/E ratio cannot be calculated for Vanda Pharmaceuticals at the moment.

What is the P/S ratio of Vanda Pharmaceuticals 2025?

The P/S cannot be calculated for Vanda Pharmaceuticals currently.

What is the Quality Investing of Vanda Pharmaceuticals?

The Quality Investing for Vanda Pharmaceuticals is 1/10.

What is the revenue of Vanda Pharmaceuticals 2025?

The expected Vanda Pharmaceuticals revenue is 290.6 M USD.

How high is the profit of Vanda Pharmaceuticals 2025?

The expected Vanda Pharmaceuticals profit is 12.09 M USD.

What is the business model of Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development, manufacturing, and marketing of innovative drugs for patients with central nervous system (CNS) disorders. The company is headquartered in Washington, D.C., USA, and operates worldwide. Vanda's product portfolio currently includes two prescription drugs used to treat sleep disorders and severe psychiatric disorders. The first of these medications is a product called Fanapt, which is approved for the treatment of schizophrenia in adults. It is an atypical antipsychotic that targets the neurotransmitter dopamine and helps reduce unusual perceptions and hallucinations. The second medication is a sleep aid called Hetlioz, which is approved for the treatment of Non-24-Hour Sleep-Wake Rhythm Disorder (Non-24) in blind individuals. Hetlioz regulates circadian rhythms that help our bodies recognize day and night cycles. People with Non-24 have difficulty recognizing and adhering to these rhythms, leading to insomnia and daytime sleepiness. Vanda Pharmaceuticals is also working on the development of other drugs, including a medication called Tradipitant for the treatment of chronic pruritus and a medication called Vanda073 for the treatment of epilepsy. Both drugs are currently in different stages of clinical development. Vanda Pharmaceuticals' business model is based on the development of innovative drugs that have a high medical need and significant market potential. The company is dedicated to developing and bringing new therapies to the market for CNS disorders to improve patients' lives and provide value to shareholders. As part of its strategy to achieve these goals, the company has formed partnerships with other pharmaceutical companies to accelerate the development and marketing of its products. Furthermore, Vanda has established a strong presence in the US and Europe and continuously works to protect its intellectual property and conduct clinical trials to obtain market approval for its drugs. Overall, Vanda Pharmaceuticals has carved out a niche in the pharmaceutical market by specializing in the development of drugs for CNS disorders. With the introduction of Hetlioz and Fanapt, the company has already achieved significant successes and has other exciting products in its development pipeline. With its strong presence in the US and Europe and strategic partnerships, Vanda has a promising future as an innovative biopharmaceutical company.

What is the Vanda Pharmaceuticals dividend?

Vanda Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Vanda Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Vanda Pharmaceuticals or the company does not pay out a dividend.

What is the Vanda Pharmaceuticals ISIN?

The ISIN of Vanda Pharmaceuticals is US9216591084.

What is the Vanda Pharmaceuticals WKN?

The WKN of Vanda Pharmaceuticals is A0JJT3.

What is the Vanda Pharmaceuticals ticker?

The ticker of Vanda Pharmaceuticals is VNDA.

How much dividend does Vanda Pharmaceuticals pay?

Over the past 12 months, Vanda Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vanda Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Vanda Pharmaceuticals?

The current dividend yield of Vanda Pharmaceuticals is .

When does Vanda Pharmaceuticals pay dividends?

Vanda Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vanda Pharmaceuticals?

Vanda Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Vanda Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vanda Pharmaceuticals located?

Vanda Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vanda Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vanda Pharmaceuticals from 2/10/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/10/2025.

When did Vanda Pharmaceuticals pay the last dividend?

The last dividend was paid out on 2/10/2025.

What was the dividend of Vanda Pharmaceuticals in the year 2024?

In the year 2024, Vanda Pharmaceuticals distributed 0 USD as dividends.

In which currency does Vanda Pharmaceuticals pay out the dividend?

The dividends of Vanda Pharmaceuticals are distributed in USD.

All fundamentals about Vanda Pharmaceuticals

Our stock analysis for Vanda Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vanda Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.